ProCE Banner Activity

CME

A Global Perspective on Biomarkers in Gastrointestinal Cancer

Multimedia
In this interactive webcast, experts discuss how the latest data on the use of biomarker-driven treatments for patients with gastrointestinal cancers affects their clinical practice.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: August 16, 2021

Expiration: August 15, 2022

No longer available for credit.

Share

Faculty

David H. Ilson

David H. Ilson, MD, PhD

Professor
Department of Medicine
Weill Cornell Medical College
Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Eric Van Cutsem

Eric Van Cutsem, MD, PhD

Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for global physicians and other healthcare professionals who treat and manage patients with gastrointestinal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the available data and expert recommendations to determine which biomarkers should be assessed in your patients with gastrointestinal malignancies
  • Plan therapeutic strategies for patients with gastrointestinal malignancies based on predictive biomarker assessment
  • Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in gastrointestinal malignancies for patient counsel and potential enrollment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

David H. Ilson, MD, PhD

Professor
Department of Medicine
Weill Cornell Medical College
Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

David H. Ilson, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, and Taiho.

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Caris, Indivumed, Daiichi Sankyo, and Taiho; salary from Indivumed; and fees for non-CME services from Bayer, Daiichi Sankyo, Merck, Pfizer, and Taiho.

Eric Van Cutsem, MD, PhD

Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

Eric Van Cutsem, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Array, Astellas, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, GlaxoSmithKline, Halozyme, Helsinn, Incyte, Ipsen, Janssen Research, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Pierre Fabre, Roche, Seattle Genetics, Servier, Sirtex, Terumo, Taiho, TRIGR, and Zymeworks and received funds for research support (paid to his institution) from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan Topping, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 16, 2021, through August 15, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to optimally integrate current and emerging biomarkers to guide treatment decisions for patients with select GI malignancies.